All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View multiple myeloma content recommended for you
Nina ShahDuring COMy 2020, Nina Shah, University of California, San Francisco, US, spoke to the Multiple Myeloma (MM) Hub about the phase Ib final analysis of isatuximab + carfilzomib.
The phase Ib study is evaluating the combination of isatuximab, an anti-CD38 monoclonal antibody, and carfilzomib, a proteasome inhibitor, for the treatment of relapsed or refractory MM. Results from this trial were previously presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, which uncovered the promising safety and efficacy profiles of the regimen.
Phase Ib final analysis — Isatuximab + carfilzomib
Your opinion matters
Which of the following factors is most important to you when selecting a treatment for patients with multiple myeloma?